So far, therapies for lymphomas and other cancers have focused on inhibition of cellular regulatory proteins (i.e., the mitoprotective members of the Bcl-2 family such as Bcl-2, Bcl-xL, and Mcl-1). Here, BCL2L1 is linked to lymphoma.